They don’t call them “Big Pharma” for nothing! Several of the industry’s biggest players decided to get bigger via M&A this year, which means next year’s ranks are going to feature at least three new players, once Wyeth and Schering-Plough are swallowed up and Roche moves over to the Top Biopharma ranks. And I do mean top!
It’s a good thing my “Pharm System” has a whole crop of new companies to move into the ranks — you're on deck, Gilead! — but how will all these mergers and consolidations affect contract service providers? Columnist Michael Martorelli has some thoughts on the subject in this issue, but pharma companies remain quiet about how they’ll reconcile their internal mega-networks with their outsourcing strategies. So stay tuned . . .
—Gil Y. Roth, Editor
|Top 20 Pharmaceutical Companies|
|07||Johnson & Johnson||$24,567|
|09||Eli Lilly & Co.||$19,285|
* PDF profiles only available for companies 17-20
All profiles written by Gil Roth, except Bayer-Schering, by Kristin Brooks.
The Lowe Down capsules written by Derek Lowe
All pipeline information compiled by Kristin Brooks
Sales information compiled by Gil Roth
Looking for the Top 10 Biopharma companies report? Look no further!